First of all to be clear; Thomas Properties Group Inc (NASDAQ: TPGI) is not a REIT. With that said, I think any real estate proposition is a Long-Term play and speculators need to stay on the sidelines. From a contrarian point of view, which I often like to take, I think real estate companies flow up with the market and when the bears come out; gold flows up, and now apparently copper and diamonds too.

I like this Company and think it undervalued by at least $1 in share valuation currently. One thing I like is its diversity. If you look at its portfolio you’ll find Thomas Properties Group Inc (NASDAQ: TPGI) owns a lot of apartments and rentable space in addition to commercial properties and parking lots. Any homebuilder will tell you that for the foreseeable future: apartments are the way to go for new construction.

The other thing I like is the regional ‘hedge’ the Company has going: its properties are in Pennsylvania, Texas, California, and Virginia. When one region suffers economically more than another, geographic diversity becomes the balancing factor to the bottom line. 

The shares have traded most of 2011 between $3 and $4.25, with normal dips and spikes and there are very few short sellers to apply any downward pressure. The stock is currently trading in the $2.77 range after the broader market bloodletting and that’s a very ‘Attractive’ entry level price for new buyer. I’ sure faithful shareholders are aggregating to hedge their positions.

The shares may not rise back to August first levels as fast as they fell, it may be an ‘immediate’ play, six weeks, but if the bulls can corner the markets in the months ahead, it will be good news for Thomas Properties Group Inc (NASDAQ: TPGI).

… just a reminder; a little profit taking during a bounce back is normal…

Seacoast Banking Corporation of Florida started July climbing up from $1.50, past $1.65, testing $1.75, and then plummeting back to $1.50, before moving up again to its current $1.62 price. Quite the ride for Shareholders in the last five weeks. 

A pretty good, but not stellar Q2 was the catalyst for all the motion. Well that’s all over now and the stock is on the move: Up. Considering its strength in testing $1.75, I think the rally is on and the shares, absent of any earth-shattering news, will retest that higher price and take, and hold it in the immediate term (6 weeks). Not many short sellers here to prevent some gains.

At Tengion Inc, the regenerative organ and tissue concern, any move up to constitute is going to be in small, incremental steps, but that doesn’t negate a rally, only makes it much more subtle in form over time. The stock was trading in the $1 range both athe beginning of June and the beginning of July, its obvious ‘bottom’ and slowly, but steadily moved up in July to its current $1.34 range, a gain of 34% in four weeks.

I think the rally is on at Tengion Inc. This was a $2.75 stock in May; it has a number to return too… Sr. Management changes in June and virtually no short sellers can sustain a rally and in the near term (3 mos) turn it into a surge.

The story at SuperGen Inc is completely different… the pharmaceutical concern, with a long list of drug candidates in the pipeline, has topped a plateau as I see it and question is: can it hold its ground. The stock was trading in the $2.80 range in late June, and in some very choppy trading fraught with little dips and spikes, the stock has managed its way to its current $3.08 price, a gain of 10% in five weeks.

With only the normal numbers of short sellers to apply any downward pressure and positive sales and EPS projections quarter over quarter; I think the rally is on here though it may be ‘two wins here and one loss there’ in weekly trading sessions.

Read more articles like this one: www.smallcapnetwork.com/Is-the-Dip-Over-.../

The stock of Phoenix Companies, the life insurance concern, has done a pretty good job in maintaining shareholder value during the last two months and I think that directly addresses its future potential. After a late May dip to $2.10 the stock bounced back in a strong fashion and opened June at $2.40.

In the last two months, the stock has vacillated between $2.30 and $2.55, a twenty five cent spread… pretty impressive to me. A lot of ‘financial sector’ companies have been clobbered during those same two months. Phoenix Companies is currently trading in the $2.35 range. While daily trading has been choppy; up and down and up and down, the Company has held its line. The Company will have an earnings call this Thursday.

Lexicon Pharmaceuticals jumped from $1.42 in late June to $1.80 in July and again, within 25 cents, has held its own in that range. July was also full of a lot of choppy trading for this stock as well with lots of little dips and spikes. The stock is currently trading in the higher end of the line at $1.79.

It was trading in this range in April. With very few short sellers, a positive quarter over quarter EPS projections, and one of its many drug candidates recently successfully completing a Phase I trial, the stock could rally a break out in the immediate term (6 weeks), and head for $2.

Over at another pharmaceutical concern, Orexigen Therapeutics, one of the ‘big three’ obesity drug investments, the story has been and remains; “All’s quiet on the Western Front.” The stock was trading in the $2 at the beginning of June and for the last two months, has, within a few cents in either direction, held that level.

It is currently trading in the lower end of that line at $1.72. With normal number of short sellers and positive sales and EPS projections, I think  Orexigen Therapeutics will stay in this range until 1) the FDA makes some relevant announcement on obesity drugs in general (which it is unlikely to do), or 2) the Company announces a new plan attack for its overall ‘obesity’ strategy.